June 5, 2019
Pillet S et al. PLoS One 2019;14(6):e0216533.
Immunogenicity and Safety of a Quadrivalent Plant-derived Virus Like Particle Influenza Vaccine Candidate – Two Randomized Phase II Clinical Trials in 18 to 49 and ≥50 Years Old Adults
You might also be interested by
Scientific Publications
Subjects at-risk for future development of rheumatoid arthritis demonstrate a PAD4-and TLR-dependent enhanced histone H3 citrullination and proinflammatory cytokine production in CD14hi monocytes
February 1, 2021
Immune Monitoring
More infoScientific Publications
Development and validation of a high-parameter mass cytometry workflow to decipher immunomodulatory changes in celiac disease
December 15, 2020
Immune Monitoring
More infoScientific Publications
Best practices for the development, analytical validation and clinical implementation of flow cytometric methods for chimeric antigen receptor T cell analyses
December 15, 2020
Immune Monitoring
More infoScientific Publications
Seroconversion stages COVID19 into distinct pathophysiological states
December 7, 2020
Immune Monitoring
More info